hTERT-immortalized MSC extracellular vesicle production platform
preclinicalplatform · high
Create scalable, standardized mesenchymal stromal cell lines that continuously produce extracellular vesicles without loss of key EV functions.
Comparison of primary mesenchymal stromal cells with hTERT-immortalized counterparts, assessing cell phenotype, EV size, number, cargo composition, and biological activity.
2026 Journal of Biotechnology study reporting that hTERT immortalization preserved key MSC and EV properties.
hTERT expression enabled stable unlimited propagation while maintaining MSC morphology, surface-marker profile, differentiation potential, and EV anti-inflammatory, anti-fibrotic, and wound-healing properties in vitro.
Large-scale extracellular vesicle production for Parkinson's disease model
preclinicalresearch program · medium
Develop and validate a scalable extracellular vesicle manufacturing protocol and test therapeutic activity in a preclinical Parkinson's disease model.
Microcarrier 3D culture of immortalized human dental pulp stem cells in a spinning bioreactor, followed by EV isolation using two-step tangential flow filtration and size exclusion chromatography; efficacy tested in a 6-hydroxydopamine rat model of Parkinson's disease.
2026 publication reporting a 463-fold EV yield increase and preclinical therapeutic evaluation in Parkinson's disease rats.
The scale-up protocol greatly increased EV yield; culture conditions affected EV miRNA content, and EV products were compared for therapeutic efficacy in vivo.
Macrophage extracellular vesicle metabolic reprogramming for bone repair
preclinicalresearch program · high
Engineer macrophage-derived extracellular vesicles with pro-regenerative properties for angiogenesis, osteogenesis, and bone repair.
Primary human macrophages were polarized or exposed to DASA-58, a PKM2-activating small molecule, then extracellular vesicle molecular cargo including microRNAs and regenerative effects were analyzed.
2026 Biomaterials study reporting metabolically dependent EV effects on angiogenesis and osteogenesis.
Metabolic modulation produced macrophage-derived EVs with hybrid pro-regenerative properties intermediate between M1 and M2 phenotypes.
Rapamycin tendon injury healing study
preclinicalresearch program · high
Test whether rapamycin treatment during early tendon injury improves Achilles tendon healing by modulating tendon cell populations and fibrosis.
Needle-induced Achilles tendon injury model in Wistar rats treated with rapamycin, with assessment of peritendinous fibrosis, tendon-core healing, cell recruitment, and circulating microRNAs.
Rodent preclinical study published in 2026.
Rapamycin reduced peritendinous fibrosis and appeared to modulate cell recruitment and circulating microRNAs, but did not improve tendon-core lesion healing up to three weeks post-injury.
RNA biomarker discovery and validation platform
undisclosedplatform · high
Support discovery, validation, diagnostics development, and analysis of RNA biomarkers for precision medicine and age-associated diseases.
Cell-free RNA profiling, including microRNAs, mRNAs, long non-coding RNAs, RNA signatures, and AI-driven analysis.
Company site describes active R&D and contract research focus across liver disease, senescence, cardiovascular disease, oncology, and bone and joint disorders.
Type 1 diabetes circulating microRNA biomarker validation
exploratorybiomarker · high
Validate circulating microRNAs as minimally invasive biomarkers for diagnosis and monitoring of long-duration type 1 diabetes in adolescents.
Case-control qPCR analysis of 23 previously reported circulating microRNAs in 24 adolescents with long-duration type 1 diabetes and 24 matched controls, with clinical and body-composition correlation analyses.
Independent validation study published in 2026 reporting 12 microRNAs with consistent differential expression between type 1 diabetes cases and controls.
miR-223-3p and miR-135a-5p were confirmed among differentially expressed candidates; miR-34a-5p associated with diabetes duration and miR-210-3p with HbA1c. Larger independent cohorts are still required for clinical translation.
